title: Combination docetaxel/vinorelbine for metastatic breast cancer and non-small-cell lung cancer.
abstract: Docetaxel (Taxotere) and vinorelbine (Navelbine) have both demonstrated activity as single agents for the treatment of patients with metastatic breast cancer and non-small-cell lung cancer. With 100 mg/m2 of docetaxel administered as a 1-hour intravenous infusion once every 3 weeks, projected median survival in previously untreated and treated patients with non-small-cell lung cancer is reported to be approximately 9 months. In addition, response rates have ranged from 23% to 36% and 17% to 21% in these respective patient populations. Preliminary studies indicate that in previously untreated patients with non-small-cell lung cancer, vinorelbine provides a survival benefit that is greater than best supportive care and similar to that of platinum-based chemotherapeutic regimens. Investigation into the use of these agents in combination is supported by synergy shown in preclinical models, nonoverlapping side-effect profiles, and the schedule independence of docetaxel. Preliminary results from phase I and II combination studies are encouraging, and no neurotoxicity has been observed. Based on these data, further study into the combined use of docetaxel and vinorelbine in patients with non-small-cell lung cancer is warranted.
authors.affiliation: Genolier Cancer Center, Switzerland.
authors.forename: M S
authors.initials: MS
authors.lastname: Aapro
mesh_terms: D000970:Antineoplastic Agents / Q000008:administration & dosage; D000972:Antineoplastic Agents, Phytogenic / Q000008:administration & dosage* / Q000009:adverse effects; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy*; D002945:Cisplatin / Q000008:administration & dosage; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D000077143:Docetaxel; D004357:Drug Synergism; D005260:Female; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy*; D009362:Neoplasm Metastasis; D009422:Nervous System Diseases / Q000139:chemically induced; D017239:Paclitaxel / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D012074:Remission Induction; D015996:Survival Rate; D043823:Taxoids; D014747:Vinblastine / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives*; D000077235:Vinorelbine
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D043823:Taxoids; D000077143:Docetaxel; D014747:Vinblastine; D017239:Paclitaxel; D002945:Cisplatin; D000077235:Vinorelbine